🔴 Dementia experts believe we are entering a defining period in the battle to treat dementia 🔍 Analysis from our health correspondent PMGallagher1
Each company has said that if its results are positive they will apply immediately for a licence from regulators in the UK, US and elsewhere. That would confirm the health condition the medicine should be used for and the recommended dosage, before going into wider use in the NHS.
. However, anti-amyloid drugs have been tried before, so some scientists are waiting until at least November before assessing the scale of any breakthrough as no trial has proved that clearing amyloid can slow down cognition decline.has dominated the dementia research field since the 90s, but if the latest approaches fail, attention will have to turn elsewhere. Lecanemab can also cause substantial side effects, the Eisai trial showed, which will need to be considered.
“If these data stand up to peer review, the drug could make a big difference and will be a fantastic example of how,” said Professor Tara Spires-Jones, group leader at the UK Dementia Research Institute at the University of Edinburgh. Worldwide, around 55 million people have dementia, with over 60 per cent living in low- and middle-income countries. As the proportion of older people in the population is increasing in nearly every country, this number is expected to rise to 78 million in 2030 and 139 million in 2050, according to the World Health Organisation.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Observing SARS-CoV-2 Omicron reinfections with different sub-variantsObserving SARS-CoV-2 Omicron reinfections with different sub-variants SARSCoV2 COVID19 Omicron Reinfection CDCgov
Read more »
What is the vaccine efficacy of repeated influenza vaccinations?In a new study, researchers calculated the decrease in vaccine effectiveness due to repeated influenza vaccinations.
Read more »
What are the differences in transmissibility between novel and emerging SARS-CoV-2 variants?What are the differences in transmissibility between novel and emerging SARS-CoV-2 variants? medrxivpreprint LSHTM Transmissibility COVID19 SARSCoV2 Variants
Read more »
Five Questions Around Biogen in Wake of the New Alzheimer's Drug DataPositive topline data from a new drug called lecanemab, which Japanese drugmaker Eisai Inc. largely developed with Biogen as its partner, has sent Biogen's shares skyrocketing.
Read more »
Study finds dimethyl fumarate was not associated with an improvement in clinical outcomes in adults hospitalized with COVID-19Study finds dimethyl fumarate was not associated with an improvement in clinical outcomes in adults hospitalized with COVID-19 medrxivpreprint UniofOxford EdinburghUni OfficialUoM unisouthampton COVID19 coronavirus covid
Read more »